 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
15 News |  |
- Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
[VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1360;
Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
- Octreosphere (octreotide extended release) / Xbrane, Sandostatin LAR Depot (octreotide acetate) / Novartis, adecatumumab (MT201) / Amgen
Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDOExpo) - Apr 1, 2020 - Abstract #ENDO2020ENDO_4099;
Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
- | citatuzumab bogatox (VB6-845) / Sesen Bio, Removab (catumaxomab) / NeoPharm, Trion, adecatumumab (MT201) / Amgen
Journal: Antibody based EpCAM targeted Therapy of Cancer, Review and update. (Pubmed Central) - Oct 2, 2019
Anti EpCAM toxin conjugated antibodies Oportuzumab Monatox (scFv antibody and Pseudomonas exotoxin A (ETA)) and Citatuzumab Bogatox (Fab fragment with bouganin toxin) and also, immono-conjugate antibody Tucotuzumab (wholly monoclonal antibody with IL2), shown acceptable results in different clinical trials. Almost, all of the antibodies were well- tolerated; however, still more clinical trials are needed for approval of the antibodies for treatment of specific tumors.
- | adecatumumab (MT201) / Amgen
Enrollment change: Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Nov 9, 2011
P2, N=35, Completed, Sponsor: Amgen Research (Munich) GmbH
Almost, all of the antibodies were well- tolerated; however, still more clinical trials are needed for approval of the antibodies for treatment of specific tumors. N=90 --> 35
- | adecatumumab (MT201) / Amgen
Trial completion: Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Nov 9, 2011
P2, N=35, Completed, Sponsor: Amgen Research (Munich) GmbH
N=90 --> 35 Active, not recruiting --> Completed